 |
New impact threshold criteria will delay introduction of drugs costing the NHS £20m per year Related items from OnMedica 75% of reappraised CDF drugs approved for NHS Kidney cancer drug approved for NHS use Give pharmacists more prescribing rights to ease GP burden Don’t let Brexit scupper UK drug discovery and delivery, MPs told MPs slam government for its poor management of Cancer Drugs Fund |
Thursday, 19 January 2017
Access to one in five new drugs approved by NICE may be delayed
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment